Reality of the ASPIRE Study

Ajai Chari, MD

Video Categories: ASH 2014

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate for a large portion of the myeloma population. The most practice changing piece of the study may be regarding the proven safety of carfilzomib.

Related Videos

November 19, 2014

Affordable High Quality Care for Patients

Ken Schaecher, MD, presents his own personal opinion on the multiple barriers to affordable high quality care for cancer patients. Supported through funding from Incyte

July 29, 2015

The Status of the Standard of Care for Cancer Patients

Dr. Alex Adjei discusses how the standard of care for cancer patients has improved overt he last few years, but there is still a great need for new treatments designed to help a broader range of cancer patients.